Information Library
Results for: Endocrinology - High-quality studies - Phase II/III
To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.
- Sort by:
- Recently Added
- Title
-
Intarcia and Quintiles Finalize Innovative Alliance
Press Release — December 13, 2011 – To speed development of a potential ground-breaking therapy for Type 2 diabetes – Intarcia Therapeutics, Inc., and Quintiles announced the signing of definitive agreements making Quintiles a financial and strategic partner for the global clinical development of Intarcia’s ITCA 650 (DUROS® continuous subcutaneous delivery of exenatide).
-
Clinical – Smarter Trials, Accelerated Outcomes
Brochure — February 16, 2011
Quintiles will work with you to plan and execute the smartest clinical trials and post-marketing studies, informed by a holistic view of strategic, operational, regulatory and marketplace issues. -
Regulatory Landscapes for Future Antidiabetic Drug Development
Hear from the Experts — May 12, 2010
In the March 2010 Journal for Clinical Studies, Dr. Erica Caveney and Dr. Rick Turner analyze the EMA Guidance on diabetes drugs and cardiovascular risk. -
New FDA Guidance on Antidiabetic Therapies
White Paper — December 11, 2009
Understanding the FDA Guidance on Assessing Cardiovascular Risks for new Antidiabetic Therapies. Learn what FDA cardiac safety requirements may mean for your development program. -
Early Phase Optimization Strategies
Media Coverage — November 18, 2009
As payers balk at rising drug prices and patent expirations threaten the industry’s revenue streams, pharmaceutical companies worldwide are looking for ways to cut costs associated with drug development and, simultaneously, speed the process up. -
Validated Biomarker Menu
Brochure — July 14, 2009
A comprehensive menu of validated cell, fluid and tissue based biomarker assays.
Page 1 of 1 (6 results)
